These tables present gross rates in U.S.$ and do not reflect any commissions payable. “Pyxis Theta” is fixed on a time charter for 12 months +/- 30 days, at $22,000 per day. “Pyxis Karteria ...

BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced ...

Maroussi, Greece – January 30, 2025 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), (“we”, “our”, “us”, the “Company” or “Pyxis Tankers”), an ...

The completion of the $3.0 million common share repurchase program demonstrates Pyxis Tankers' commitment to returning value to shareholders and potentially enhancing share price. Redemption of ...

This Pyxis Oncology sponsored trial is investigating the novel extracellular targeting ADC PYX-201 in combination with pembrolizumab in multiple indications including but not limited to ...

Shares of NASDAQ PYXS opened at $1.57 on Friday. The company’s 50-day moving average price is $1.65 and its 200 day moving average price is $2.94. Pyxis Oncology has a 52 week low of $1.39 and a ...

Maroussi, Greece – January 30, 2025 – Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), (“we”, “our”, “us”, the “Company” or “Pyxis Tankers”), an international shipping company, announced today key ...

Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. Dr. Sullivan continued, "Treatment options for many patients with advanced solid tumors remain limited, and we are eager to ...

Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...

Maroussi, Greece - January 30, 2025 - Pyxis Tankers Inc. (NASDAQ Cap Mkts: PXS), ("we”, "our”, "us”, the "Company” or "Pyxis Tankers”), an international shipping company, announced today key ...